Page
%P
-
Article
Open AccessAzacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34+ blood cells to pre-empt relapse in patients with CD34+ myelodysplastic s...
-
Chapter
Substanzprofile: Zytostatika, Hormone, Zytokine1
-
Article
Open AccessIndustry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations
The purpose of this analysis of health economic studies in the field of oncology was to investigate among sponsored studies whether any relationship could be established between the type of sponsorship and (1)...